Core Viewpoint - Enanta Pharmaceuticals, Inc. has announced an upsized underwritten public offering of 6,500,000 shares at a price of $10.00 per share, with the offering expected to close on October 2, 2025, pending customary conditions [1]. Company Summary - Enanta Pharmaceuticals is a clinical-stage biotechnology company focused on developing small molecule drugs for virology and immunology indications [1]. - The entire offering of shares is being made by Enanta Pharmaceuticals [1].